All In Biotech

Drug Trial Radar · NCT03627767

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS

Last checked: Nov 19, 2026Latest source record: Sep 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,235 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,235

Actual

Start

Jun 11, 2018

Primary completion

Sep 2, 2020

Study completion Oct 7, 2020

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 13, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. Subjects responding well to an initial open-label 12 week treatment of PF-04965842 (200 mg) taken orally once daily (QD) will be identified and randomized in a double-blind manner to receive 200 mg QD PF-04965842, 100 mg QD PF-04965842, or QD placebo. Efficacy and safety of 2 doses of PF-04965842 will be evaluated relative to placebo over 40 weeks. Subjects experiencing significant worsening of their symptoms, i.e., protocol-defined flare, enter 12 weeks rescue treatment and receive 200 mg PF-04965842 together with a marketed topical medicine. Eligible patients will have the option to enter a long-term extension study after completing the initial 12 week treatment, the 12 week rescue treatment, and the 40 week blinded treatment.

Conditions

  • Dermatitis
  • Dermatitis, Atopic
  • Eczema
  • Skin Diseases
  • Skin Diseases, Genetic
  • Genetic Diseases, Inborn
  • Skin Diseases, Eczematous
  • Hypersensitivity
  • Hypersensitivity, Immediate
  • Immune System Diseases

Interventions

  • PF-04965842 100 mgDrug

    PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 40 weeks

  • PF-04965842 200 mgDrug

    PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 40 weeks

  • PlaceboDrug

    Placebo, administered as two tablets to be taken orally once daily for 40 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Loss of Response: Double-blind (DB) PeriodTime frame: From Day 1 of up to Week 40 of double blind period
  2. Time to Loss of Response: Double-blind PeriodTime frame: From date of first dose of randomized treatment until the last dose of randomized treatment (if not entered rescue) or first day of rescue treatment (if entered rescue) (maximum up to Week 40, visit window was extended +/- 45 Days due to COVID 19)

Locations

235 sites in 21 countries. Site status is shown where the registry gives one.

  • Total Skin and Beauty Dermatology Center, PC

    Birmingham, Alabama

  • University of Alabama at Birmingham, Dermatology at the Whitaker Clinic

    Birmingham, Alabama

  • Clinical Research Center of Alabama, LLC

    Birmingham, Alabama

  • Tien Q Nguyen MD Inc dba First OC Dermatology

    Fountain Valley, California

  • Center for Dermatology Clinical Research, Inc.

    Fremont, California

  • Beach Allergy and Asthma Specialty Group, A Medical Corporation

    Long Beach, California

  • Dermatology Specialists, Inc.

    Oceanside, California

  • University of California San Diego

    San Diego, California

  • San Luis Dermatology and Laser Clinic

    San Luis Obispo, California

  • Southern California Dermatology, Inc.

    Santa Ana, California

  • Mosaic Dermatology

    Santa Monica, California

  • Bay Pines VAHCS

    Bay Pines, Florida

  • Skin Care Research, LLC

    Boca Raton, Florida

  • Skin Research Institute

    Coral Gables, Florida

  • Baumann Cosmetic and Research Institute

    Miami, Florida

  • Park Avenue Dermatology

    Orange Park, Florida

  • USF Asthma, Allergy & Immunology Clinical Research Unit

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • Dermatologic Surgery Specialists, PC

    Macon, Georgia

  • Midwest Allergy Sinus Asthma, SC

    Normal, Illinois

  • NorthShore University HealthSystem Dermatology Clinical Trials Unit

    Skokie, Illinois

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • Ds Research

    New Albany, Indiana

  • The Indiana Clinical Trials Center

    Plainfield, Indiana

  • Kansas City Dermatology, P.A.

    Overland Park, Kansas

  • DXP Imaging

    Louisville, Kentucky

  • Skin Sciences PLLC

    Louisville, Kentucky

  • Qualmedica Research, LLC

    Owensboro, Kentucky

  • Owensboro Dermatology Associates

    Owensboro, Kentucky

  • Meridian Clinical Research, LLC

    Baton Rouge, Louisiana

  • Tulane University Health Sciences Center

    New Orleans, Louisiana

  • Tufts Medical Center

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • MediSearch Clinical Trials

    Saint Joseph, Missouri

  • Saint Louis University Dermatology

    St Louis, Missouri

  • Forest Hills Dermatology Group

    Kew Gardens, New York

  • Juva Skin and Laser Center

    New York, New York

  • UR Dermatology at College Town

    Rochester, New York

  • M3 - Wake Research, Inc.

    Raleigh, North Carolina

  • Bexley Dermatology Research

    Bexley, Ohio

Showing 40 of 235 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.